Certain medicinal fungi, particularly species like Ganoderma lucidum (Reishi), Cordyceps sinensis, and Lentinula edodes (Shiitake), have been traditionally used in Asian medicine for overall health, including cardiovascular support. In recent decades, scientific studies have begun to evaluate these claims. The most substantial evidence relates to their bioactive compounds—such as beta-glucans, triterpenoids, sterols, and polysaccharides—which exhibit cholesterol-lowering, anti-inflammatory, and antioxidant effects in preclinical and some clinical studies.

For example, small randomized controlled trials and animal studies have shown that extracts from Reishi and Shiitake can modestly reduce LDL cholesterol and improve lipid profiles. Some studies also suggest antiplatelet and antihypertensive effects, which could theoretically lower cardiovascular risk. Cordyceps has been shown in animal models to improve endothelial function and reduce cardiac injury after ischemia. However, most human trials to date are small, of short duration, and often of varying quality.

Overall, while laboratory and some clinical evidence points to potential cardiovascular benefits, these findings are not yet robust or consistent enough to support widespread medical use for cardiovascular disease management. More large-scale, well-designed clinical trials are needed to establish efficacy and safety. Thus, the evidence level is moderate (3/5), with promising but not conclusive support.